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In this issue of Cancer Cell, Huang et al. report that preventing exit from mitosis provides a very efficient
strategy for killing cells. Although this is not an unexpected finding, it nevertheless provides a novel concep-
tual framework for augmenting the antimitotic strategies currently under development for fighting cancer.The mitotic spindle has long been a useful
target for chemotherapy (reviewed in
Jordan and Wilson, 1998). The various
spindle poisons used in the clinic prevent
stable attachment of spindle microtu-
bules to kinetochores and therefore in-
hibit satisfaction of the mitotic checkpoint
(MC). Failure to satisfy this checkpoint
significantly retards the degradation of
cyclin B1, which results in a sustained
mitotic arrest (reviewed in Musacchio
and Hardwick, 2002).
Despite what we know regarding the
action of spindle poisons, it remains
unclear how they kill cells. The current
consensus is that prolonging mitosis
spindle poisons induces some cells to
die in mitosis, although others can ‘‘slip’’
through the checkpoint into the next G1
as tetraploid cells (reviewed in Rieder
and Maiato, 2004). However, cells that
undergo mitotic slippage may or may not
die in the subsequent G1. p38/p53-profi-
cient cells that escape cell death undergo
a permanent G1 arrest in a tetraploid state
after slippage, while cells lacking p38 or
p53 can undergo additional rounds of
division to produce highly aneuploid
progeny (Figure 1).
Recent live-cell imaging studies have
provided important new insights into
how normal and cancer cells respond
to various spindle poisons. First, it is
now clear that mitotic slippage occurs
because cyclin B is slowly degraded in
the background of a fully active MC (Brito
and Rieder, 2006). It is also evident that
cancer cell lines are more sensitive to
spindle poisons than nontransformed
cells (Brito and Rieder, 2009; Gascoigne
and Taylor, 2008; Orth et al., 2008; Shi
et al., 2008). These studies also clearly
show that the duration a cell spends in
mitosis does not strictly determine274 Cancer Cell 16, October 6, 2009 ª2009whether it will live or die, challenging the
longstanding idea that it is the duration
of the mitotic arrest that dictates cell
fate. Perhaps the most surprising conclu-
sion from these studies was, however,
that the response to a spindle poison is
not necessarily predetermined by genetic
background or the type of drug. In the
presence of the same drug cells within a
single cell line display variable cell fates,
which is clearly demonstrated by the
fact that the fate of one daughter cell is
independent of that of the other derived
from the same mother (Gascoigne and
Taylor, 2008).
So if the fate of a cell after spindle
disruption cannot be predicted based on
its genetics, how is it determined? Gas-
coigne and Taylor proposed an elegant
‘‘competing-networks’’ model for cell
fate in spindle poisons (Gascoigne and
Taylor, 2008, 2009). One of these net-
works works to maintain the mitotic con-
dition by preventing cyclin B degradation
(via the MC), while the other works to acti-
vate the apoptotic machinery. In their
model mitotic slippage occurs when
cyclin B drops below a critical threshold,
whereas cell death occurs when the
apoptosis-activating network reaches a
critical threshold. During a delay in mito-
sis, both networks are active and the
network that eventually prevails deter-
mines cell fate. The model draws some
support from data that delaying slippage
by simply increasing the level of cyclin B
is sufficient to enhance death in mitosis
(Gascoigne and Taylor, 2008).
The information from these studies
defined the starting point for the Huang
et al. (2009) investigation reported in this
issue of Cancer Cell. They reasoned that
drugs that block cells in mitosis without
allowing mitotic slippage should kill cellsElsevier Inc.more efficiently than current antimitotic
drugs. Because mitotic slippage occurs
through the slow ‘‘background’’ degrada-
tion of cyclin B, and because normal
exit from mitosis also requires cyclin B
destruction, Huang and coworkers tested
their idea by inhibiting the degradation of
cyclin B. They did this by either express-
ing a nondegradable mutant of cyclin B
or depleting an essential cofactor (Cdc20)
required for activating the E3 ubiquitin
ligase complexes (APCs) responsible
for targeting cyclin B for proteolysis
(reviewed in Musacchio and Hardwick,
2002). As predicted, both strategies killed
cancer cells more effectively than drugs
that simply perturb the mitotic spindle
(Figure 1).
So why the excitement? Considering
that spindle poisons have long been sus-
pected to kill tumor cells by causing a pro-
tracted mitotic arrest, the finding that an
irreversible arrest is a more efficient killer
does not really come as a surprise.
However, in sharp contrast to drugs that
target the spindle, the MC becomes
rapidly satisfied (just like in a normal
mitosis) when Cdc20 is depleted or in
the presence of nondegradable cyclin B,
but the cell remains stuck in mitosis.
Under this condition cell death occurs
independent of MC activity (Huang et al.,
2009). This strongly suggests that a proa-
poptotic signal slowly accumulates during
mitosis that is not dependent on spindle
damage or the inability to satisfy the MC,
and that if this signal breaches its critical
threshold before mitotic exit occurs, it
will invariably trigger death in mitosis.
None of the currently available drugs
that target mitosis, including inhibitors
for kinesin-5, Polo, or Aurora kinases,
prevent the degradation of cyclin B. As
a result their efficacy is limited because
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Figure 1. Blocking Mitotic Exit as an Antitumor Strategy
Conventional spindle poisons interfere with the assembly of a normal bipolar spindle. Taxanes and vinca
alkaloids directly target the microtubules of the spindle and interfere with microtubule dynamics that are
essential for proper attachment of chromosomes, while inhibition of Eg5, Polo, or Aurora A causes forma-
tion of a monopolar spindle. All of these drugs can cause a prolonged mitotic arrest in cultured cells and
many have been shown to display tumor selectivity. However, cells can escape from this arrest by mitotic
slippage, after which a cell can die in the subsequent G1, undergo a permanent arrest, or continue on
through additional cell cycles. It is noteworthy that clinically effective drug concentrations are likely to
be well below that needed to arrest cultured cells in mitosis. An outstanding question therefore remains
whether antimitotics really ‘‘arrest’’ tumor cells in mitosis in situ, or if the mitotic delay induced by lower
drug concentrations induces cell death during the ensuing G1. Drugs that block mitotic exit would prevent
mitotic slippage, and Huang et al. demonstrate that this strategy is highly efficient in promoting mitotic cell
death, even in the absence of spindle damage. Nonetheless, it is currently unclear if this type of strategy
will display tumor-selective cell killing. Combining spindle poisons with drugs that block mitotic exit could
potentially provide sufficient tumor selectivity (see text for details).they allow some cells to escape death in
mitosis by slipping into the next G1. With
this in mind the findings of Huang and
colleagues provide a novel conceptual
framework for maximizing the efficiency
of antimitotic drugs for killing cells. Their
work suggests that drugs that target
Cdc20, or other components involved in
cyclin B degradation including the APCs
or proteasomes, may prove more effec-
tive in killing cells. In principle, such drugs
could be combined with established
spindle poisons: one would prolong mito-
sis by preventing satisfaction of the MC
while the other would prevent mitotic slip-
page by inhibiting the degradation of
cyclin B (Figure 1).
Although this approach for killing cells
in mitosis may well prove superior to other
drug-based strategies, how can it be
made tumor selective? Clearly, if the
proapoptotic machinery becomes pro-
gressively more aggressive during a pro-longed mitosis, then cell killing in
response to spindle poisons will not be
limited to tumor cells. Yet, compared to
nontransformed cells, tumor cell lines
appear more prone to dying in mitosis in
response to spindle poisons (Brito and
Rieder, 2009; Gascoigne and Taylor,
2008; Orth et al., 2008; Shi et al., 2008),
suggesting that they more easily reach
the apoptosis threshold, possibly be-
cause they are ‘‘primed for death’’ (Green,
2007). Thus, the necessary tumor-selec-
tivity might be achieved by combining
a drug that delays mitotic exit with
a drug that promotes apoptosis. Drugs
that prevent degradation of cyclin B will
not produce this selectivity because
cyclin B degradation is essential for
normal cells to exit mitosis. Of course it
is possible that simply slowing cyclin B
degradation could provide enough time
to breach the apoptosis barrier and selec-
tively induce mitotic cell death in someCancer Celltumors. Selectivity may also be achieved
via the route by which cells are arrested
in mitosis. For example, tumor cells
with aberrant numbers of centrosomes
depend on the microtubule motor protein
HSET (Kwon et al., 2008), which clusters
the extra centrosomes and allows proper
bipolar spindle assembly. It is therefore
possible that combining drugs that target
HSET with drugs that inhibit mitotic exit
will provide a highly selective treatment
for tumors that display centrosome ampli-
fication.
All in all the study by Huang and
coworkers provides a new antitumor
strategy that is based on inhibiting mitotic
slippage by preventing cyclin B degrada-
tion, while enhancing cell death in mitosis
by lowering the threshold for apoptotic-
induced death in mitosis. Both strategies
require further study of how their corre-
sponding and competing networks are
wired to enable the eventual development
of drugs that can target these networks in
a highly selective manner.
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